Baidu
map

Diabetes Care:服用β-受体阻滞剂的2型糖尿病患者强化降糖治疗有效吗?

2016-10-08 xing.T MedSci原创

由此可见,对于接受β-受体阻滞剂治疗的2型糖尿病患者而言,强化降糖治疗可能是有效的治疗方法。

最近研究表明,β-受体阻滞剂可以降低低血糖的不良影响,减少低血糖相关心律失常和死亡风险。近日,糖尿病领域权威杂志《Diabetes Care》发表了日本东京学者的研究文章,旨在评估接受β受体阻滞剂治疗的糖尿病患者,与标准的血糖治疗相比,进行强化血糖治疗能否有效预防心血管事件和不增加死亡率。

研究者采用Cox比例风险模型,提取控制糖尿病患者心血管风险行动(ACCORD)的试验数据来评估3079例接受β受体阻滞剂治疗的糖尿病患者和7145例未接受β受体阻滞剂治疗的糖尿病患者的心血管事件风险以及全因死亡和心血管死亡风险。

研究者发现:与标准治疗组相比,接受β-受体阻滞剂治疗的糖尿病患者强化治疗组的心血管事件累积发生率明显降低(风险比为0.81;95%可信区间为0.67–0.97;P=0.02),而在未接受β-受体阻滞剂治疗的糖尿病患者这种差异不显著(风险比为0.92;95%可信区间为0.78–1.09;P=0.36)。相反,接受β-受体阻滞剂治疗的糖尿病患者的全因死亡和心血管事件累积发生率在标准治疗组和强化治疗组之间无统计学差异(全因死亡:风险比为1.08;95%可信区间为0.83–1.42;P=0.54;心血管死亡:风险比为1.05;95%可信区间为0.72–1.51;P=0.79),而在未接受β-受体阻滞剂治疗的糖尿病患者,强化治疗组的全因死亡和心血管事件累积发生率均显著高于标准治疗组(全因死亡:风险比为1.25;95%可信区间为1.02–1.52;P=0.02;心血管死亡:风险比为1.43;95%可信区间为1.03–1.98;P=0.03)。

由此可见,对于接受β-受体阻滞剂治疗的2型糖尿病患者而言,强化降糖治疗可能是有效的治疗方法。

原始出处:

Tetsuro Tsujimoto,et al. Intensive Glycemic Therapy in Patients With Type 2 Diabetes on β-Blockers. Diabetes Care 2016 Oct; 39(10): 1818-1826.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (13)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1901469, encodeId=e3fd1901469f5, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu Aug 03 13:04:00 CST 2017, time=2017-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995133, encodeId=924b199513319, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Fri Jan 20 11:04:00 CST 2017, time=2017-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637501, encodeId=fe77163e501f8, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Dec 17 02:04:00 CST 2016, time=2016-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633067, encodeId=b9b8163306e25, content=<a href='/topic/show?id=84da981e6db' target=_blank style='color:#2F92EE;'>#降糖治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98176, encryptionId=84da981e6db, topicName=降糖治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1af122008128, createdName=neurosurgeon, createdTime=Mon Sep 04 14:04:00 CST 2017, time=2017-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003846, encodeId=97362003846be, content=<a href='/topic/show?id=4d8650150ce' target=_blank style='color:#2F92EE;'>#强化降糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50150, encryptionId=4d8650150ce, topicName=强化降糖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3547346, createdName=dongjia2010, createdTime=Mon Oct 31 08:04:00 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759780, encodeId=20e41e59780c2, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Feb 12 15:04:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085734, encodeId=1b032085e3404, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Sun Jan 22 03:04:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145687, encodeId=9f7914568ec9, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:15:31 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145686, encodeId=b1e01456864d, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:15:16 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145685, encodeId=55f814568535, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:14:18 CST 2016, time=2016-10-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1901469, encodeId=e3fd1901469f5, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu Aug 03 13:04:00 CST 2017, time=2017-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995133, encodeId=924b199513319, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Fri Jan 20 11:04:00 CST 2017, time=2017-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637501, encodeId=fe77163e501f8, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Dec 17 02:04:00 CST 2016, time=2016-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633067, encodeId=b9b8163306e25, content=<a href='/topic/show?id=84da981e6db' target=_blank style='color:#2F92EE;'>#降糖治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98176, encryptionId=84da981e6db, topicName=降糖治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1af122008128, createdName=neurosurgeon, createdTime=Mon Sep 04 14:04:00 CST 2017, time=2017-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003846, encodeId=97362003846be, content=<a href='/topic/show?id=4d8650150ce' target=_blank style='color:#2F92EE;'>#强化降糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50150, encryptionId=4d8650150ce, topicName=强化降糖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3547346, createdName=dongjia2010, createdTime=Mon Oct 31 08:04:00 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759780, encodeId=20e41e59780c2, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Feb 12 15:04:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085734, encodeId=1b032085e3404, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Sun Jan 22 03:04:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145687, encodeId=9f7914568ec9, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:15:31 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145686, encodeId=b1e01456864d, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:15:16 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145685, encodeId=55f814568535, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:14:18 CST 2016, time=2016-10-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1901469, encodeId=e3fd1901469f5, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu Aug 03 13:04:00 CST 2017, time=2017-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995133, encodeId=924b199513319, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Fri Jan 20 11:04:00 CST 2017, time=2017-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637501, encodeId=fe77163e501f8, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Dec 17 02:04:00 CST 2016, time=2016-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633067, encodeId=b9b8163306e25, content=<a href='/topic/show?id=84da981e6db' target=_blank style='color:#2F92EE;'>#降糖治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98176, encryptionId=84da981e6db, topicName=降糖治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1af122008128, createdName=neurosurgeon, createdTime=Mon Sep 04 14:04:00 CST 2017, time=2017-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003846, encodeId=97362003846be, content=<a href='/topic/show?id=4d8650150ce' target=_blank style='color:#2F92EE;'>#强化降糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50150, encryptionId=4d8650150ce, topicName=强化降糖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3547346, createdName=dongjia2010, createdTime=Mon Oct 31 08:04:00 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759780, encodeId=20e41e59780c2, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Feb 12 15:04:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085734, encodeId=1b032085e3404, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Sun Jan 22 03:04:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145687, encodeId=9f7914568ec9, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:15:31 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145686, encodeId=b1e01456864d, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:15:16 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145685, encodeId=55f814568535, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:14:18 CST 2016, time=2016-10-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1901469, encodeId=e3fd1901469f5, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu Aug 03 13:04:00 CST 2017, time=2017-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995133, encodeId=924b199513319, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Fri Jan 20 11:04:00 CST 2017, time=2017-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637501, encodeId=fe77163e501f8, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Dec 17 02:04:00 CST 2016, time=2016-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633067, encodeId=b9b8163306e25, content=<a href='/topic/show?id=84da981e6db' target=_blank style='color:#2F92EE;'>#降糖治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98176, encryptionId=84da981e6db, topicName=降糖治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1af122008128, createdName=neurosurgeon, createdTime=Mon Sep 04 14:04:00 CST 2017, time=2017-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003846, encodeId=97362003846be, content=<a href='/topic/show?id=4d8650150ce' target=_blank style='color:#2F92EE;'>#强化降糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50150, encryptionId=4d8650150ce, topicName=强化降糖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3547346, createdName=dongjia2010, createdTime=Mon Oct 31 08:04:00 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759780, encodeId=20e41e59780c2, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Feb 12 15:04:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085734, encodeId=1b032085e3404, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Sun Jan 22 03:04:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145687, encodeId=9f7914568ec9, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:15:31 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145686, encodeId=b1e01456864d, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:15:16 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145685, encodeId=55f814568535, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:14:18 CST 2016, time=2016-10-11, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1901469, encodeId=e3fd1901469f5, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu Aug 03 13:04:00 CST 2017, time=2017-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995133, encodeId=924b199513319, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Fri Jan 20 11:04:00 CST 2017, time=2017-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637501, encodeId=fe77163e501f8, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Dec 17 02:04:00 CST 2016, time=2016-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633067, encodeId=b9b8163306e25, content=<a href='/topic/show?id=84da981e6db' target=_blank style='color:#2F92EE;'>#降糖治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98176, encryptionId=84da981e6db, topicName=降糖治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1af122008128, createdName=neurosurgeon, createdTime=Mon Sep 04 14:04:00 CST 2017, time=2017-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003846, encodeId=97362003846be, content=<a href='/topic/show?id=4d8650150ce' target=_blank style='color:#2F92EE;'>#强化降糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50150, encryptionId=4d8650150ce, topicName=强化降糖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3547346, createdName=dongjia2010, createdTime=Mon Oct 31 08:04:00 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759780, encodeId=20e41e59780c2, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Feb 12 15:04:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085734, encodeId=1b032085e3404, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Sun Jan 22 03:04:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145687, encodeId=9f7914568ec9, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:15:31 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145686, encodeId=b1e01456864d, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:15:16 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145685, encodeId=55f814568535, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:14:18 CST 2016, time=2016-10-11, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1901469, encodeId=e3fd1901469f5, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu Aug 03 13:04:00 CST 2017, time=2017-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995133, encodeId=924b199513319, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Fri Jan 20 11:04:00 CST 2017, time=2017-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637501, encodeId=fe77163e501f8, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Dec 17 02:04:00 CST 2016, time=2016-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633067, encodeId=b9b8163306e25, content=<a href='/topic/show?id=84da981e6db' target=_blank style='color:#2F92EE;'>#降糖治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98176, encryptionId=84da981e6db, topicName=降糖治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1af122008128, createdName=neurosurgeon, createdTime=Mon Sep 04 14:04:00 CST 2017, time=2017-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003846, encodeId=97362003846be, content=<a href='/topic/show?id=4d8650150ce' target=_blank style='color:#2F92EE;'>#强化降糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50150, encryptionId=4d8650150ce, topicName=强化降糖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3547346, createdName=dongjia2010, createdTime=Mon Oct 31 08:04:00 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759780, encodeId=20e41e59780c2, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Feb 12 15:04:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085734, encodeId=1b032085e3404, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Sun Jan 22 03:04:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145687, encodeId=9f7914568ec9, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:15:31 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145686, encodeId=b1e01456864d, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:15:16 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145685, encodeId=55f814568535, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:14:18 CST 2016, time=2016-10-11, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1901469, encodeId=e3fd1901469f5, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu Aug 03 13:04:00 CST 2017, time=2017-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995133, encodeId=924b199513319, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Fri Jan 20 11:04:00 CST 2017, time=2017-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637501, encodeId=fe77163e501f8, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Dec 17 02:04:00 CST 2016, time=2016-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633067, encodeId=b9b8163306e25, content=<a href='/topic/show?id=84da981e6db' target=_blank style='color:#2F92EE;'>#降糖治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98176, encryptionId=84da981e6db, topicName=降糖治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1af122008128, createdName=neurosurgeon, createdTime=Mon Sep 04 14:04:00 CST 2017, time=2017-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003846, encodeId=97362003846be, content=<a href='/topic/show?id=4d8650150ce' target=_blank style='color:#2F92EE;'>#强化降糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50150, encryptionId=4d8650150ce, topicName=强化降糖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3547346, createdName=dongjia2010, createdTime=Mon Oct 31 08:04:00 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759780, encodeId=20e41e59780c2, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Feb 12 15:04:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085734, encodeId=1b032085e3404, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Sun Jan 22 03:04:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145687, encodeId=9f7914568ec9, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:15:31 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145686, encodeId=b1e01456864d, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:15:16 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145685, encodeId=55f814568535, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:14:18 CST 2016, time=2016-10-11, status=1, ipAttribution=)]
    2017-01-22 zhyy88
  8. [GetPortalCommentsPageByObjectIdResponse(id=1901469, encodeId=e3fd1901469f5, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu Aug 03 13:04:00 CST 2017, time=2017-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995133, encodeId=924b199513319, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Fri Jan 20 11:04:00 CST 2017, time=2017-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637501, encodeId=fe77163e501f8, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Dec 17 02:04:00 CST 2016, time=2016-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633067, encodeId=b9b8163306e25, content=<a href='/topic/show?id=84da981e6db' target=_blank style='color:#2F92EE;'>#降糖治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98176, encryptionId=84da981e6db, topicName=降糖治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1af122008128, createdName=neurosurgeon, createdTime=Mon Sep 04 14:04:00 CST 2017, time=2017-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003846, encodeId=97362003846be, content=<a href='/topic/show?id=4d8650150ce' target=_blank style='color:#2F92EE;'>#强化降糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50150, encryptionId=4d8650150ce, topicName=强化降糖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3547346, createdName=dongjia2010, createdTime=Mon Oct 31 08:04:00 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759780, encodeId=20e41e59780c2, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Feb 12 15:04:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085734, encodeId=1b032085e3404, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Sun Jan 22 03:04:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145687, encodeId=9f7914568ec9, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:15:31 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145686, encodeId=b1e01456864d, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:15:16 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145685, encodeId=55f814568535, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:14:18 CST 2016, time=2016-10-11, status=1, ipAttribution=)]
    2016-10-11 知难而进

    继续关注!

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1901469, encodeId=e3fd1901469f5, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu Aug 03 13:04:00 CST 2017, time=2017-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995133, encodeId=924b199513319, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Fri Jan 20 11:04:00 CST 2017, time=2017-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637501, encodeId=fe77163e501f8, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Dec 17 02:04:00 CST 2016, time=2016-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633067, encodeId=b9b8163306e25, content=<a href='/topic/show?id=84da981e6db' target=_blank style='color:#2F92EE;'>#降糖治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98176, encryptionId=84da981e6db, topicName=降糖治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1af122008128, createdName=neurosurgeon, createdTime=Mon Sep 04 14:04:00 CST 2017, time=2017-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003846, encodeId=97362003846be, content=<a href='/topic/show?id=4d8650150ce' target=_blank style='color:#2F92EE;'>#强化降糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50150, encryptionId=4d8650150ce, topicName=强化降糖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3547346, createdName=dongjia2010, createdTime=Mon Oct 31 08:04:00 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759780, encodeId=20e41e59780c2, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Feb 12 15:04:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085734, encodeId=1b032085e3404, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Sun Jan 22 03:04:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145687, encodeId=9f7914568ec9, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:15:31 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145686, encodeId=b1e01456864d, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:15:16 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145685, encodeId=55f814568535, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:14:18 CST 2016, time=2016-10-11, status=1, ipAttribution=)]
    2016-10-11 知难而进

    谢谢分享!

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1901469, encodeId=e3fd1901469f5, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu Aug 03 13:04:00 CST 2017, time=2017-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995133, encodeId=924b199513319, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Fri Jan 20 11:04:00 CST 2017, time=2017-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637501, encodeId=fe77163e501f8, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Dec 17 02:04:00 CST 2016, time=2016-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633067, encodeId=b9b8163306e25, content=<a href='/topic/show?id=84da981e6db' target=_blank style='color:#2F92EE;'>#降糖治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98176, encryptionId=84da981e6db, topicName=降糖治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1af122008128, createdName=neurosurgeon, createdTime=Mon Sep 04 14:04:00 CST 2017, time=2017-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003846, encodeId=97362003846be, content=<a href='/topic/show?id=4d8650150ce' target=_blank style='color:#2F92EE;'>#强化降糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50150, encryptionId=4d8650150ce, topicName=强化降糖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3547346, createdName=dongjia2010, createdTime=Mon Oct 31 08:04:00 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759780, encodeId=20e41e59780c2, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Feb 12 15:04:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085734, encodeId=1b032085e3404, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Sun Jan 22 03:04:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145687, encodeId=9f7914568ec9, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:15:31 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145686, encodeId=b1e01456864d, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:15:16 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145685, encodeId=55f814568535, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:14:18 CST 2016, time=2016-10-11, status=1, ipAttribution=)]
    2016-10-11 知难而进

    谢谢分享!

    0

相关资讯

ADA 2014:低血糖是否增加心血管事件?

强化降糖治疗增加低血糖事件,但是低血糖事件是否增加心血管事件?在ADA 2014上,ORIGIN研究、ACCORD研究和VADT研究的研究者报告了新的循证医学证据。来自瑞典的吕登(Lars E.Ryden)教授报告在ORIGIN研究中,相对于口服降糖药组,甘精胰岛素组低血糖事件更多,包括严重低血糖和非严重低血糖,但是甘精胰岛素组心血管风险却低于口服降糖药组。美国杜克大学法因格罗斯(Mark N.

Lancet:强化降糖或有助于减少T2DM患者缺血性心脏病

加拿大与美国学者联合研究表明,对于2型糖尿病(T2DM)伴其他心血管危险因素的中年人而言,血糖浓度升高是其缺血性心脏病可控制的危险因素。文章8月1日在线发表于《柳叶刀》(Lancet)杂志。研究简介研究纳入ACCORD试验中10251例成年T2DM患者,随机接受强化或标准降糖治疗[目标糖化血红蛋白(HbA1c)水平分别为<6.0%或7.0%~7.9%]。评估积极治疗期间(平均 3.7年)及总

Lancet Diab & Endo:强化降糖降心梗糖尿病患者死亡率(DIGAMI1研究)

瑞典学者研究发现,对于发生急性心梗和入院时存在高糖血症的糖尿病患者,强化血糖控制对其生存时间有长期影响。论文5月13日在线发表于《柳叶刀糖尿病与内分泌学》(Lancet Diabetes Endocrinol)杂志。 该项名为DIGAMI1的研究纳入620例先前有或未被诊为糖尿病、血糖浓度>11 mmol/L、过去24小时有可疑急性心梗的患者,患者被随机(1:1)分为以胰岛素为基础的强化血

Lancet Diab & Endo:强化降糖延长糖尿病合并急性心梗患者生存期

控制血糖对糖尿病患者预防微血管疾病而言至关重要,但强化血糖控制预防大血管并发症和增加生存率证据尚不充分。 糖尿病合并急性心梗强化胰岛素治疗(DIGAMI1)研究平均3.4年随访数据表明与传统治疗相比,糖尿病合并急性心梗强化胰岛素治疗减少11%死亡率。但是,此种死亡率减少获益持续时间尚不清楚。 为此,瑞典卡罗林斯卡学院Ritsinger教授等对DIGAMI1研究随访20年数据进行分析研究

EASD 2014:强化降糖未能使大血管长期获益

研究简介ADVANCE 研究纳入11140 例年龄≥55 岁的2型糖尿病患者(病程>10年),随机分入标准血糖控制组或强化血糖控制组。强化治疗组接受格列齐特缓释片联合其他药物,以将糖化血红蛋白(HbA1c) 控制在≤6.5%。主要终点为主要大血管事件及微血管事件。中位随访5年后,强化治疗组平均HbA1c(6.5%)显著低于标准治疗组(7.3%)。强化治疗组可降低主要大血管和微血管事件复合发生率(1

JAMA:1型糖尿病强化降糖7年与长期低死亡率有关(DCCT研究)

1型糖尿病强化血糖疗法是否能减少死亡率,目前仍然存在争议。本研究旨在观察二者之间的关系。研究采用DCCT(糖尿病控制和并发症试验)队列中长期随访人群,以确定二者之间关系。DCCT(1983-1993年)人群纳入结束,直到2012年12月31日随访结束,共有1441名糖尿病患者参与其中,在基线时为13〜39岁,病程为1至15年。当时没有或早期有微血管并发症,没有高血压,先前存在的心血管疾病,或其他潜

Baidu
map
Baidu
map
Baidu
map